Take a look at this month’s industry headlines including Priority Review for two antibacterial agents from Merck (NJ, USA), a clinical trial for a new malaria drug and the launch of omadacycline in the USA.
Take a look at this month’s industry headlines including an FDA approval for a vaccine protecting against six diseases, positive clinical trial results for bacteraemia and dengue vaccines and new funding for CRSIPR-based antimicrobials.
The UK government has published a 20-year vision and a 5-year national action plan for how the UK will contribute to controlling and containing antimicrobial resistance by 2040.
New partnerships for antibiotic discovery and further cuts in the field: December’s industry headlines
Take a look at this month’s industry headlines including a new partnership for antibiotic development, approval for HIV drugs and authorization for a cytomegalovirus test.
Positive results for zoliflodacin, EMA approval for fexinidazole and Merck cuts rotavirus commitment – take a look a the month’s industry headlines.
Researchers from the University of Zurich have discovered that thanatin, a compound produced naturally by the spined soldier bug, could target Gram-negative bacteria by preventing formation of the bacteria’s outer membrane – an unprecedented mechanism.
A Phase II, muti-center, randomized, open-label trial has reported that a novel oral antibiotic, zoliflodacin, is effective in the treatment of uncomplicated urogenital gonorrhea.
The US FDA has granted priority review for Sanofi Pasteur’s dengue vaccine, Dengvaxia®, despite its controversial past.
Roche has announced the FDA approval of Xofluza™, the first and only single-dose oral medicine approved to treat flu.
The US FDA has approved Paratek Pharmaceuticals’ antibiotic Nuzyra™ (omadacycline) for the treatments of adults with community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections.